Free Trial
CVE:KNE

Kane Biotech (KNE) Stock Price, News & Analysis

Kane Biotech logo
C$0.10 +0.01 (+5.56%)
As of 09:30 AM Eastern

About Kane Biotech Stock (CVE:KNE)

Key Stats

Today's Range
C$0.10
C$0.10
50-Day Range
C$0.09
C$0.12
52-Week Range
C$0.09
C$0.17
Volume
2,000 shs
Average Volume
57,368 shs
Market Capitalization
C$13.69 million
P/E Ratio
2.38
Dividend Yield
3.08%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Remove Ads
Receive KNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kane Biotech and its competitors with MarketBeat's FREE daily newsletter.

KNE Stock News Headlines

Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
Kane Biotech Inc KNE
See More Headlines

KNE Stock Analysis - Frequently Asked Questions

Kane Biotech's stock was trading at C$0.11 on January 1st, 2025. Since then, KNE shares have decreased by 13.6% and is now trading at C$0.10.
View the best growth stocks for 2025 here
.

Shares of KNE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kane Biotech investors own include Mason Resources (LLG), Datametrex AI (DM) and Allstar Health Brands (ALST).

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
CVE:KNE
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
2.38
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$6.03 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$1.42 million
Cash Flow
C$0.01 per share
Price / Cash Flow
8.50
Book Value
C($0.01) per share
Price / Book
-18.46

Miscellaneous

Free Float
N/A
Market Cap
C$13.69 million
Optionable
Not Optionable
Beta
0.52
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (CVE:KNE) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners